A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand
Gail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, Janaki Amin, Rungsun Rerknimitr, Panusit Petcharapirat, Pip Marks, Joe Sasadeusz, David A Cooper, Scott Bowden, Stephen Locarnini, Kiat Ruxrungtham, Gregory J Dore
Hepatology | WILEY | Published : 2008
UNLABELLED: Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is associated with considerable liver disease morbidity and mortality. Emerging HIV epidemics in areas of high HBV endemicity such as Asia are expanding the population with HIV/HBV coinfection. Limited randomized trial data exist to support current guidelines for HBV combination therapy in HIV/HBV coinfection. The objective of this prospective randomized clinical trial was to compare the strategy of HBV monotherapy with lamivudine (LAM) or tenofovir disoproxil fumarate (TDF) versus HBV combination therapy with LAM/TDF in antiretroviral-naïve HIV/HBV-coinfected subjects in Thailand. Thirty-six HIV/HBV-..View full abstract
supported by Gilend Sciences.